Miami, FL – May 19, 2020 (EmergingGrowth.com NewsWire) — EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies, Mateon Therapeutics, Inc. (OTCQB: MATN).
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN, in an article titled “COVID-19: 200 Candidated and Counting” https://www.genengnews.com/covid-19-candidates/covid-19-keeping-an-eye-on/mateon-therapeutics/ has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress.
● FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
● DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data.
● KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
● TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
Among those is OT-101 – an interesting technology, attracting notable partners, or both. Mateon therapeutics (OTCQB:MATN) is developing OT-101 against COVID-19 and recently filed an IND with US FDA to allow it to start clinical trial against COVID-19. OT-101 targets not only viral replication but often-lethal clinical sequelae of COVID-19, including pneumonia and fibrosis—which according to Mateon gives its treatment an efficacy and safety index on par or superior to Gilead Sciences’ remdesivir. OT-101 has also shown broad efficacy against solid tumors across multiple Phase II oncology trials, including pancreatic cancer, glioblastoma, and melanoma (Study P001) and in high-grade gliomas (Study G004), the company said.
“I am encouraged that Alhelfawi M.  and Chen W.  put forth hypothesis that inhibition of TGF-β as treatment of COVID-19.” said Dr. Vuong Trieu, CEO of Mateon Therapeutics.
 Alhelfawi M. Potential approach for fighting against corona virus disease. ASRJETS. 2020;66:127-144.
 Chen W. A potential treatment of COVID-19 with TGF-β blockade. International Journal of Biological Sciences. 2020;16(11):1954-1955. Doi: 10.7150/ ijbs.46891.
EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies. Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.